The global Biosimulation Market was valued at USD 4.1 billion in 2025 and is projected to reach USD 14.8 billion by 2033, expanding at a CAGR of 17.3% from 2026 to 2033. North America dominated the market with a 44.2% revenue share in 2025, while Asia Pacific is expected to record the fastest growth during the forecast period. Increasing drug resistance in diseases such as cancer, tuberculosis, and bacterial infections is strengthening demand for biosimulation tools in drug development and research.

Biosimulation Market Growth Drivers

The increasing regulatory acceptance of model-informed drug development is accelerating the adoption of biosimulation across the pharmaceutical industry. Regulatory agencies such as the U.S. FDA are increasingly supporting pharmacokinetic/pharmacodynamic modeling, physiologically based pharmacokinetic modeling, and clinical trial simulation to improve drug development efficiency and optimize dose selection.

The growing focus on personalized medicine is also increasing demand for biosimulation platforms capable of modeling patient-specific therapeutic responses. Biosimulation can incorporate variations in genetics, physiology, and disease progression to support optimized dosing, therapeutic efficacy, and reduced adverse drug reactions.

At the same time, increasing drug development activity and technological advancements are encouraging researchers to integrate biosimulation into early-stage development. The integration of artificial intelligence and machine learning is creating additional opportunities by improving data analysis, predictive modeling, and pattern recognition.

Download a free sample report or claim your copy of this full market intelligence report

Biosimulation Market Segmentation Shows Strong Software Demand

The software segment accounted for 59.4% of revenue in 2025, supported by increasing availability of application-specific platforms for predictive modeling, dose optimization, toxicity assessment, and virtual clinical trial simulation. AI-integrated platforms are further improving computational efficiency and predictive accuracy.

The drug development segment held the largest application share of 55.4% in 2025. Biosimulation enables researchers to create detailed models of biological systems and supports drug development processes, including pharmacogenomics and pharmacogenetics.

Within therapeutic areas, oncology held the largest revenue share in 2025, as biosimulation helps researchers model tumor dynamics, treatment responses, genomic information, and pharmacokinetics. The infectious diseases segment is expected to grow at the fastest CAGR, supported by modeling of pathogen behavior, host responses, treatment effects, and drug resistance.

Cloud Deployment and Flexible Pricing Support Adoption

The cloud-based deployment model held more than 43.0% of revenue in 2025 and is expected to grow at the fastest CAGR. Cloud platforms provide flexibility to scale computational resources according to operational requirements while reducing the infrastructure investments associated with traditional on-premises systems.

The license-based pricing model held the largest revenue share in 2025, offering organizations access to sophisticated biosimulation tools through different licensing options. Meanwhile, subscription-based models are expected to grow rapidly as they enable organizations to manage budgets and provide broader access to advanced simulation technologies.

Looking for more in-depth data focusing on specific segments or regions? Get this report customized with inclusion of custom data sets to suit your exact business needs.

Biosimulation Market Regional Outlook

North America accounted for the largest 44.2% revenue share in 2025, supported by the presence of key players, pharmaceutical R&D investments, chronic disease prevalence, and regulatory acceptance of in-silico models.

The U.S. biosimulation market benefits from early adoption of model-informed drug development approaches and strong FDA support for PBPK and QSP modeling. High utilization across oncology, rare disease, and biologics development is further supporting growth.

Europe benefits from a strong pharmaceutical and biotechnology research base and increasing R&D investments. The UK market is supported by pharmaceutical companies, CROs, CDMOs, and collaborations involving biosimulation providers. Germany held the largest market share in Europe in 2025, supported by healthcare spending and strong R&D infrastructure.

Asia Pacific is expected to register the fastest CAGR from 2026 to 2033. Pharmaceutical and biopharmaceutical manufacturing expansion, increasing CRO and CDMO presence, precision medicine, AI-driven drug discovery, and rising biotechnology investments are strengthening adoption across China, Japan, South Korea, and India.

Key Biosimulation Companies

The competitive landscape includes companies pursuing partnerships, technology development, and expansion activities to strengthen their market positions. Key companies profiled in the biosimulation market include Certara, Dassault Systèmes, Advanced Chemistry Development, Inc. (now part of Revvity), Simulations Plus, Schrodinger, Inc., and Chemical Computing Group ULC.

Explore the full list of profiled companies operating in this market with recent strategic initiatives

Innovation remains a defining characteristic of the market as companies integrate AI and machine learning into biosimulation platforms. Partnerships and collaborations are also supporting the development of AI-enabled drug discovery and digital twin technologies.

Biosimulation Market Outlook

The biosimulation market is moving toward increasingly integrated, AI-enabled, and cloud-based drug development workflows. Regulatory support, personalized medicine, growing pharmaceutical R&D activity, and the need to address drug resistance are expected to sustain market expansion through 2033. As pharmaceutical and biotechnology companies seek more predictive and efficient development approaches, biosimulation is positioned to play an increasingly important role in modern drug discovery and development.

Explore our dedicated business services:

• U.S. Healthcare Facility Mapping & Intelligence Portal – Claims analytics (MS-DRG, service lines, ICD-10 outpatient, APC reimbursement, CPT-level) plus hospital-level financials (balance sheet, income statement, uncompensated care, financial health dashboards), covering 25,000+ healthcare facilities — including 7,000+ hospitals, independent pharmacies, freestanding EDs, concierge physicians, and ASCs.
• Brainshare Consulting – End-to-end business consulting services including Opportunity assessment, GTM support, Competitive intelligence, and Consumer Analytics.
• Custom Research – Get a market intelligence report tailored to your specific requirements and aligned with your business goals.
• Consumer Insights – Capture real, evolving consumer sentiment and behavior to help you make data driven strategies.
• Horizon Databooks – Access the world’s largest portal of Market Reports & Statistics
• Investment Insights – Make investment decisions with data driven insights, powered by domain and technology
• Signal (Pricing Intelligence) - Commodity price intelligence to drives strategic advantage.

About us:
Grand View Research, a market research and consulting company, provides syndicated research reports, customized research reports, and consulting services. Grand View Research database is used by the world's renowned academic institutions and Fortune 500 companies to understand the global and regional business environment. Our database features thousands of statistics and in-depth analysis on 46 industries in 25 major countries worldwide.